Bosutinib-induced massive pleural effusion: Cross-intolerance with all tyrosine kinase inhibitors.
Nevin Alayvaz AslanHande Oğul HıncalÖzde ElverVeysel ErolNil GülerPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2022)
Cross-intolerance is an important problem in the tyrosine kinase inhibitor era. The significance of this case is the development of cross-intolerance to all second-generation tyrosine kinase inhibitors and furthermore to a third-generation tyrosine kinase inhibitor. Management strategies for pleural effusion and close follow-up are important.